| 1.1 0.01 (0.92%) | 10-13 11:05 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.57 | 1-year : | 1.86 |
| Resists | First : | 1.34 | Second : | 1.6 |
| Pivot price | 1.13  |
|||
| Supports | First : | 0.93 | Second : | 0.77 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.17 |
| MA(100) : | 1.77 |
MA(250) : | 3.38 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.9 |
D(3) : | 25 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 9.47 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XCUR ] has closed above bottom band by 39.4%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.09 - 1.1 | 1.1 - 1.1 |
| Low: | 1.05 - 1.05 | 1.05 - 1.06 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Fri, 09 Oct 2026
Exicure Stock Price Forecast. Should You Buy XCUR? - StockInvest.us
Mon, 28 Sep 2026
Exicure Inc. (XCUR) Slips to $1.22 as Shares Press Against Nearby Support - PSAR Stop - https://www.siam.in/
Wed, 16 Sep 2026
Nasdaq gives Exicure until Dec. 2 to show it has $2.5 million left after debts - Stock Titan
Mon, 03 Aug 2026
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - The Manila Times
Mon, 03 Aug 2026
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics - Quiver Quantitative
Mon, 13 Jul 2026
How Exicure Inc. (XCUR) Affects Rotational Strategy Timing - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 41.4 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.4 % |
| Return on Equity (ttm) | -168.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.19 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.8 |
| PEG Ratio | 0 |
| Price to Book value | 7.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|